Inhibition assays showed that, JQ1 clinical trial while caspase-3 could be effectively inhibited by XIAP, survivin had no detectable inhibitory activity against the enzyme, even at concentrations several thousand-fold higher than XIAP. Our finding supports the premise that survivin does not directly inhibit effector caspases.”
“This analysis assessed the effect of lenalidomide

on progression-free survival (PFS). Patients with relapsed or refractory multiple myeloma (RRMM) who received lenalidomide plus dexamethasone in the MM-009 and MM-010 trials were pooled and those who had not progressed and were still receiving lenalidomide at 12 months were included. The median follow-up of surviving patients was 48 months. Of 353 patients who received lenalidomide plus dexamethasone, 116 (33%) had not progressed. Overall, 52 patients (45%) had no dose reductions, 25 (22%) had dose reductions >= 12 months and 39 (34%) had dose reductions Elacridar in vivo before 12 months. Patients who had dose reductions >= 12 months had a significantly longer median PFS than those who had reductions before 12 months (P = 0.007)

or no dose reductions (P = 0.039) (not reached vs 28.0 vs 36.8 months, respectively). In a multivariate Cox regression model, dose reduction >= 12 months was an independent predictor of improved PFS (hazard ratio, 0.47; 95% confidence interval, 0.23-0.98) after adjusting for patient characteristics. The data suggest that to achieve maximum PFS benefit, most patients with RRMM should be treated for >= 12 months with full-dose lenalidomide plus dexamethasone. Thereafter, patients may benefit from lower-dose continued therapy; prospective studies are needed to confirm these findings. Leukemia (2011) 25, 1620-1626; doi:10.1038/leu.2011.126; published online 12 July 2011″
“Introduction: This study was undertaken to investigate the effect of paclitaxel and bevacizumab on the therapeutic efficacy of Y-90-labeled B3 monoclonal antibody, directed against Le(y) antigen, for the treatment of Le(y)-positive A431 tumors implanted subcutaneously in the right hind flank of nude

mice.

Methods: When the tumor size reached similar to 200 mm(3), the mice received a single dose of intravenous (iv) Y-90-labeled B3 (60 mu Ci/150 mu g or 100 mu Ci/150 mu g B3), intraperitoneal paclitaxel (40 mg/kg) or iv bevacizumab (5 mg/kg) for monotherapy. To investigate the effect of combined therapies on survival, the mice were treated with two or three agents in the following combinations: Y-90-B3 on day 0 and paclitaxel on day 1; bevacizumab on -1 day and Y-90-B3 on day -1; bevacizumab on 1 day and paclitaxel on day 1; bevacizumab, Y-90-B3 and paclitaxel each at I-day intervals. The mice with no treatment were used as a control. The tumor volume at 1000 mm3 was used as a surrogate end point of survival.

Results: Compared to control animals, paclitaxel delayed tumor growth with a significantly longer median survival time (P<.